Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G6 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information.

Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility.

 

Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.

 

Data from collaborator devices and products must be verified by those collaborator devices and products. Users should confirm data and connections with their collaborator devices and products.

The Dexcom G6 Continuous Glucose Monitoring System (Dexcom G6 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older.

Thomas Grace, MD is a paid spokesperson for Dexcom. Dr. Grace is a guest on this episode of the podcast.

Dexcom G6 System User Guide

 

Safety Information

 

About Hello Dexcom

 

About Freestyle Libre System

 

Libre 3 user guide available here, including information about sensor survival rate, which was 68.3% at 14 days.

 

Dexcom Follow app: The Dexcom G6 App allows you to share your glucose data with up to 10 people. By downloading the Dexcom Follow App, followers can view your glucose data directly from their smart device whether they live down the street or across the country. Separate Follow App required. For a list of compatible devices, visit www.dexcom.com/compatibility.

 

Connectivity – basics (https://provider.dexcom.com/dexcom-cgm/collaborators)

Time in Range: Recommendations from the International Consensus on Time in Range, 2019 recommend individualized glycemic targets for high risk and/or older adults with a focus on reducing the percentage of time spent less than 70 md/dL and preventing excessive hyperglycemia. Everyone’s treatment plan is different, talk to your healthcare provider before changing your Time in Range settings.

Dexcom, Dexcom Follow, Dexcom CLARITY, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries.

References:

1.          Steven V. Edelman, Nicholas B. Argento, Jeremy Pettus, Irl B. Hirsch; Clinical Implications of Real-time and Intermittently Scanned Continuous Glucose Monitoring. Diabetes Care 1 November 2018; 41 (11): 2265–2274. https://doi.org/10.2337/dc18-1150

2.          Visser MM, et al.; Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial. Lancet. 2021 Jun 12;397(10291):2275-2283. https://doi.org/10.1016/S0140-6736(21)00789-3

Learn more about your ad choices. Visit megaphone.fm/adchoices